Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study

The neurological disorder affects approximately 2.9 million people worldwide

- PMLiVE

Alnylam shares positive phase 3 results for vutrisiran in ATTR with cardiomyopathy

The company said it will be proceeding with regulatory filings for the therapy later this year

Clipboard inside Cuttsy+Cuttsy branded shapes

Closing the loop: Why clinical trial results matter to participants

Discover why sharing clinical trial results with participants is crucial for respect, informed health decisions, and fostering strong researcher-participant partnerships.

Cuttsy + Cuttsy

- PMLiVE

GSK’s RSV vaccine Arexvy approved by EC for use in adults aged 50 to 59 years

An estimated 20 million adults in this age population are at an increased risk of severe RSV outcomes

- PMLiVE

UK government launches £400m investment programme to support clinical research

Up to 18 clinical trial hubs will be created to accelerate the development of new drugs

- PMLiVE

Breast cancer drug found to help slow growth of rare childhood brain tumour

Researchers discovered that targeting the CDK6 protein could make tumour cells vulnerable to treatment

- PMLiVE

Wilmington Healthcare has relaunched as HSJ Information

The new company covers HSJ, HSJ Advisory, HSJ Marketing Solutions and HSJ Market Intelligence

Bridging Gaps with Virtual Meetings – Perks of Virtual Medical Education

Learn how virtual meetings can be used to review new data and minimize lengthy presentations, making every in-person interaction more productive and focused. Dive into the synergistic benefits of combining...

Impetus Digital

Bayer symbol

Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

The companies will advance small molecule therapeutics against a new class of targets for cancer

- PMLiVE

Roche’s monoclonal antibody PiaSky approved by EC to treat rare blood disorder PNH

The drug is now the first monthly subcutaneous treatment authorised for use in this patient population

EU flag

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

Artificial intelligence versus real insight – does pharmaceutical industry consulting face a dilemma or a progression?

By Frank Fisher and Zoë van Helmond

Amiculum

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links